Year-over-year articles
NYKODE THERAPEUTICS ASA
20 crawlable comparisons of consecutive annual reports.
Full company analysis · Org.nr 990 646 066
Shrank 95% on revenue, stronger earnings, fresh owner capital
Comparing Årsregnskap 2025 with 2024 for NYKODE THERAPEUTICS ASA. Revenue 9.16m NOK → 453.0k NOK (-95.1%). Net result -38.48m NOK → -12.67m NOK. Equity…
Shrank 31% on revenue
Comparing Årsregnskap 2024 with 2023 for NYKODE THERAPEUTICS ASA. Revenue 13.36m NOK → 9.16m NOK (-31.5%). Net result -33.39m NOK → -38.48m NOK. Equity…
Grew 48% on revenue, fresh owner capital
Comparing Årsregnskap 2023 with 2022 for NYKODE THERAPEUTICS ASA. Revenue 9.03m NOK → 13.36m NOK (+48.0%). Net result -41.68m NOK → -33.39m NOK. Equity…
Shrank 75% on revenue, weaker earnings
Comparing Årsregnskap 2022 with 2021 for NYKODE THERAPEUTICS ASA. Revenue 35.77m NOK → 9.03m NOK (-74.8%). Net result -8.60m NOK → -41.68m NOK. Equity…
Shrank 83% on revenue, slipped into loss, cash halved-plus
Comparing Årsregnskap 2021 with 2020 for NYKODE THERAPEUTICS ASA. Revenue 215.69m NOK → 35.77m NOK (-83.4%). Net result +149.77m NOK → -8.60m NOK. Equity…
Grew 1633% on revenue, returned to profit
Comparing Årsregnskap 2020 with 2019 for NYKODE THERAPEUTICS ASA. Revenue 12.45m NOK → 215.69m NOK (+1633.0%). Net result -13.70m NOK → +149.77m NOK. Equity…
Fresh owner capital
Comparing Årsregnskap 2019 with 2018 for NYKODE THERAPEUTICS ASA. Revenue 12.04m NOK → 12.45m NOK (+3.4%). Equity 140.07m NOK → 268.44m NOK.
Grew 23% on revenue
Comparing Årsregnskap 2018 with 2017 for NYKODE THERAPEUTICS ASA. Revenue 9.76m NOK → 12.04m NOK (+23.3%). Equity 203.53m NOK → 140.07m NOK.
Grew 8% on revenue
Comparing Årsregnskap 2017 with 2016 for NYKODE THERAPEUTICS ASA. Revenue 9.00m NOK → 9.76m NOK (+8.5%). Equity 234.40m NOK → 203.53m NOK.
Grew 60% on revenue, fresh owner capital
Comparing Årsregnskap 2016 with 2015 for NYKODE THERAPEUTICS ASA. Revenue 5.62m NOK → 9.00m NOK (+60.0%). Equity 17.63m NOK → 234.40m NOK.
Shrank 36% on revenue
Comparing Årsregnskap 2015 with 2014 for NYKODE THERAPEUTICS ASA. Revenue 8.73m NOK → 5.62m NOK (-35.6%). Equity 30.16m NOK → 17.63m NOK.
Grew 76% on revenue, fresh owner capital
Comparing Årsregnskap 2014 with 2013 for NYKODE THERAPEUTICS ASA. Revenue 4.95m NOK → 8.73m NOK (+76.3%). Equity 9.23m NOK → 30.16m NOK.
Grew 332% on revenue, fresh owner capital
Comparing Årsregnskap 2013 with 2012 for NYKODE THERAPEUTICS ASA. Revenue 1.15m NOK → 4.95m NOK (+332.2%). Equity 108.6k NOK → 9.23m NOK.
Shrank 13% on revenue, fresh owner capital
Comparing Årsregnskap 2012 with 2011 for NYKODE THERAPEUTICS ASA. Revenue 1.32m NOK → 1.15m NOK (-13.2%). Equity 340.8k NOK → 108.6k NOK.
Grew 2489% on revenue
Comparing Årsregnskap 2011 with 2010 for NYKODE THERAPEUTICS ASA. Revenue 51.0k NOK → 1.32m NOK (+2488.9%). Equity 2.93m NOK → 340.8k NOK.
Shrank 95% on revenue, fresh owner capital
Comparing Årsregnskap 2010 with 2009 for NYKODE THERAPEUTICS ASA. Revenue 935.7k NOK → 51.0k NOK (-94.5%). Equity 737.6k NOK → 2.93m NOK.
Grew 36% on revenue, stronger earnings, cash halved-plus
Comparing Årsregnskap 2009 with 2008 for NYKODE THERAPEUTICS ASA. Revenue 688.0k NOK → 935.7k NOK (+36.0%). Net result +670.5k NOK → +906.4k NOK. Equity…
Stronger earnings
Comparing Årsregnskap 2008 with 2007 for NYKODE THERAPEUTICS ASA. Net result +963 NOK → +670.5k NOK. Equity 436.2k NOK → -234.4k NOK.
Weaker earnings
Comparing Årsregnskap 2007 with 2006 for NYKODE THERAPEUTICS ASA. Net result +961.3k NOK → +963 NOK. Equity 100.3k NOK → 436.2k NOK.
First published accounts
First year in the published series for NYKODE THERAPEUTICS ASA (2006). No prior-year comparative in this dataset.